Role of anabolic testosterone agents and structured exercise to promote recovery in ICU survivors
- 6 August 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Critical Care
- Vol. 26 (5) , 508-515
Abstract
Purpose of review: ICU survivors frequently suffer significant, prolonged physical disability. ‘ICU Survivorship’, or addressing quality-of-life impairments post-ICU care, is a defining challenge, and existing standards of care fail to successfully address these disabilities. We suggest addressing persistent catabolism by treatment with testosterone analogues combined with structured exercise is a promising novel intervention to improve ‘ICU Survivorship’. Recent findings: One explanation for lack of success in addressing post-ICU physical disability is most ICU patients exhibit severe testosterone deficiencies early in ICU that drives persistent catabolism despite rehabilitation efforts. Oxandrolone is an FDA-approved testosterone analogue for treating muscle weakness in ICU patients. A growing number of trials with this agent combined with structured exercise show clinical benefit, including improved physical function and safety in burns and other catabolic states. However, no trials of oxandrolone/testosterone and exercise in nonburn ICU populations have been conducted. Summary: Critical illness leads to a catabolic state, including severe testosterone deficiency that persists throughout hospital stay, and results in persistent muscle weakness and physical dysfunction. The combination of an anabolic agent with adequate nutrition and structured exercise is likely essential to optimize muscle mass/strength and physical function in ICU survivors. Further research in ICU populations is needed.Keywords
This publication has 59 references indexed in Scilit:
- Exercise rehabilitation for patients with critical illness: a randomized controlled trial with 12 months of follow-upCritical Care, 2013
- Functional Disability 5 Years after Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2011
- Burns: where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs?Current Opinion in Clinical Nutrition and Metabolic Care, 2011
- Long-term complications of critical careCritical Care Medicine, 2011
- Therapeutic Effects of Nandrolone and Testosterone in Adult Male HIV Patients With AIDS Wasting Syndrome (AWS): A Randomized, Double-Blind, Placebo-Controlled TrialHIV Research & Clinical Practice, 2010
- Update on clinical trials of growth factors and anabolic steroids in cachexia and wastingThe American Journal of Clinical Nutrition, 2010
- Bench-to-bedside review: Mobilizing patients in the intensive care unit – from pathophysiology to clinical trialsCritical Care, 2009
- Pharmacology of anabolic steroidsBritish Journal of Pharmacology, 2008
- The Effect of Oxandrolone on the Endocrinologic, Inflammatory, and Hypermetabolic Responses During the Acute Phase PostburnAnnals of Surgery, 2007
- The Effects of Oxandrolone and Exercise on Muscle Mass and Function in Children With Severe BurnsPediatrics, 2007